Opens in a new tab
Lean Seal ISO website iv removebg
ALWAYS AUDIT READY
Feasibility Inquiry

Your CRO Needs a Dedicated Network of Sites and a Culture of Connectedness

|Clinical Cost Drivers|Cost by Trial Phase
Share

How collaborating with an experienced, specialized CRO with a history of best practice will positively impact your oncology drug development processes.

Whether in Canada or any other region, as a first-in-class Sponsor there is no question that quality does matter when choosing a CRO that will effectively contribute to your drug development process.  With the rapidly evolving complexity of oncology clinical trials, being first-in-class throughout the drug development process is critical. There are a number of best practices and key attributes that characterize ‘winning’ sponsors and distinguish them as first-in-class. Matching these characteristics similarly with those of an experienced, specialized CRO with proven oncology expertise is a good formula for success in conducting your clinical trials.

Some of the key attributes that distinguish first-in-class drug development companies is that they have good science, are dynamic and excel in effective communication, value relationships and engaged vendors, and are keenly interested in investigators and dedicated site networks made available to them by their study partners.

Common goals the first-in-class drug developer and specialized CRO partner should share are a commitment to: reliable and top-quality service delivery, faster results, greater value from everyone involved, and fewer hiccups and costs. Trials today conducted by mid-size and smaller drug developers have multiple vendors of up to 15 or more involved in the trial, and this is increasingly becoming the norm rather than the exception. Associated with this is of course that more people are sitting around the table at meetings, as well as the increasing number of SOPs, processes, and study manuals that apply for each trial.

Clinical Cost Drivers

In 2024 the estimated development cost of a single compound (including failed drugs and opportunity cost) was $2.6B with the per patient cost estimate at $36.5k. And the cost of running clinical trials remains a major portion of the overall drug development cost. Among the key clinical trial cost drivers are CRO services composing roughly 26-41% of clinical trial cost.

Due to the required level of specialization, oncology indications are best served by monitoring conducted exclusively by CRAs who possess oncology expertise. This niche expertise increases monitoring costs and the need to carefully select for stable, specialized options when choosing regional CROs with which to partner for your oncology trials. Notably aim to engage stable and reliable study teams, and select sites involved early in the development of your program to allow a deep understanding of the agent and study design.

Cost by Trial PhaseWherever possible keeping this knowledge and experience onboard as you progress into later development phases is of real value. There is significant retraining and logistics costs associated with changing the extended team and/or sites involved at each phase of an oncology clinical trial. Problems encountered with the drug, with the treatment, with some aspect of logistics, are valuable lessons learned. With a stable and reliable CRO monitoring team it’s possible to leverage these lessons as the program progresses from one phase to the next to prevent recurrences of these problems.

Connect with a Dedicated Network of Sites & Meet All Milestones: Recommended Actions

1) Engage an extended Team with robust oncology & clinical research experience

2) Set low turnover as a critical success factor for engagement of your extended team

3) Make a careful and critical examination for local, in-depth understanding and applied knowledge of known and ‘behind-the-scenes’ site policies & particularities

4) Never underestimate the Importance of Trust: In clinical research as everywhere, teams are made up of people, and people work most effectively for and with those they trust

5) Every PI relies on their trusted support staff to undertake their clinical research studies, so in your study regions engage vendors with strong, long-standing site relationships within a dedicated site network

Scimega a LEAN Niche Canadian CRO

For over a quarter of a century now our successful, niche CRO thrives by providing mid-size and smaller study Sponsors a depth of oncology expertise and clinical trial operations experience in Canada. Conducted through a dedicated National network of oncology clinical sites that often emerge among top enrollers in global studies. Scimega is well managed, with low turnover, and a clinical operations team populated with LEAN Coached experts in oncology that follows your program development over the long term. At Scimega the same project team follows a Sponsor’s program from Phase I to II and subsequently heads any scale-up to Phase III that follows. Thereby providing not only the necessary therapeutic alignment of personnel, but also the accessible knowledge of what is and has gone on with a study program from its outset.

Throughout its history Scimega has been dedicated to continuous improvement at the core of the value it provides. In every instance Scimega works with your team to devise innovative solutions to address your unique challenges, bringing together the right combination of specialized expertise for your cutting-edge oncology trial.Scimega’s team of LEAN Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the LEAN trajectory.

If you’re interested in learning more about the Canadian opportunity, explore an expansion with us!

 

Contributed by: Julie Martin, President & CEO